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Abstract The protein kinase D family of enzymes consists of
three isoforms: PKD1/PKCW, PKD2 and PKD3/PKCX. They
all share a similar architecture with regulatory sub-domains that
play speci¢c roles in the activation, translocation and function
of the enzymes. The PKD enzymes have recently been impli-
cated in very diverse cellular functions, including Golgi organi-
zation and plasma membrane directed transport, metastasis,
immune responses, apoptosis and cell proliferation.
( 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Second messengers play an important role in the onset of
many signaling pathways. Recently, a new family of diacyl-
glycerol (DAG)-stimulated serine/threonine protein kinases
has been identi¢ed. It comprises three members: PKD1 (pro-
tein kinase D1) or its human homolog protein kinase CW
(PKCW) [1,2], PKD2 [3] and PKD3 (also named PKCX) [4].
Initially, PKCW and PKCX were labeled as members of the
PKC family [2], creating a new subgroup of the PKCs. How-
ever, their only similarity to other PKCs resides in a C1 do-
main that is homologous to the DAG binding domain of
other PKC enzymes, and they lack the C2 domain responsible
for Ca2þ sensitivity of the conventional PKC subgroup [1,2].
Additionally, in contrast to PKC family members, the cata-
lytic domain of PKD shows a very low homology to the
conserved kinase domain of the PKCs and displays a distinct
inhibitor and substrate speci¢city [5^7]. The NH2-terminal
part of PKD contains a pleckstrin homology (PH) domain
and lacks the typical autoinhibitory pseudosubstrate motif
present in PKCs [1]. These di¡erences made it di⁄cult to
classify PKD1, 2 and 3 in the PKC family and recently they
were classi¢ed as a novel subgroup of the calcium/calmodulin-
dependent protein kinase (CAMK) family, based on sequence
similarities of the kinase domain [8].
PKD has recently been implicated in the organization of the
Golgi apparatus, regulating the ¢ssion of vesicles from the
trans-Golgi network (TGN) [9]. Several reports identify
PKD as a regulator of cell proliferation and apoptosis, pro-
posing a role for the enzyme in carcinogenesis [10^13]. More-
over, PKD appears to be an important regulator of very dif-
ferent intracellular signaling pathways [14^20].
In this minireview we take a closer look at the di¡erent
members of the PKD family, pointing at their similarities
and, when known, at their di¡erences.
2. PKD: structure^function relationship and mechanism of
activation
PKD1, 2 and 3 share a similar modular structure (illus-
trated in Fig. 1), consisting of an N-terminal regulatory do-
main and a C-terminal kinase domain. The N-terminus of
both PKD1 and PKD2 starts with an apolar region, rich in
alanine and/or proline residues. In PKD3 this hydrophobic
domain is absent. The three isoforms contain two cysteine-
rich Zn ¢ngers, separated by an exceptionally long Zn-¢nger
linker region (usually only 14^20 amino acids long in PKCs).
Moreover, in PKD2 this linker region contains a serine-rich
stretch. In all three isoforms, the Zn ¢ngers precede a region
rich in negatively charged amino acids and a PH domain.
The molecular architecture of PKD is without doubt related
to the enzyme’s regulation. PKD1 kinase activity is regulated
intramolecularly, and PKD2 and PKD3, because of their sim-
ilar structure, may share common interacting factors and reg-
ulation characteristics. The regulatory domain of PKD1 exerts
an inhibitory e¡ect on the kinase activity, since the deletion of
this domain leads to full activation of PKD1 [21]. Moreover,
individual regions within the regulatory domain of PKD1
seem to have an inhibitory e¡ect. Mutations in the PH do-
main lead to full activation of PKD1 [22]. Hence the binding
of GLQ could activate PKD1 [23] by interfering with the in-
teraction of the PH domain with the catalytic subunit, or by
displacing the association of an inhibitory ligand. PKD1 is
also fully activated when both Zn ¢ngers are deleted [24].
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Recent ¢ndings show that only Zn ¢nger 2 binds phorbol
dibutyrate (PDBu) with high a⁄nity [25], hence the two Zn
¢ngers are functionally di¡erent. Zn ¢nger 1 has a speci¢c
inhibitory e¡ect on the catalytic activity of PKD1, but seems
to have minor importance in PDBu binding. In contrast, Zn
¢nger 2 is not essential for the PDBu-induced activation of
the kinase, but necessary for the PDBu-dependent transloca-
tion of PKD1 [24,25]. Consequently, activation and translo-
cation of PKD1 are two separate features. For PKD2 and
PKD3, one could predict a similar function for the di¡erent
sub-domains. However, one should bear in mind that small
sequence di¡erences could have profound regulatory or func-
tional consequences.
PKD1 can be activated in vivo by at least three di¡erent
mechanisms. Several agents are known to activate PKD1
through the activation of phospholipase C (PLC), leading to
production of DAG and thereby activating PKCO and/or
PKCR, which in turn phosphorylates PKD1 in the activation
loop. A recent report has shown that this activation occurs
through the release of autoinhibition of the PH domain, and
that the activation loop phosphorylation is the mechanistic
trigger for this process [26]. Apart from DAG^PLC^PKC-de-
pendent activation of PKD, GLQ subunits can activate PKD1
through direct interaction with the PH domain [23], thereby
regulating the restructuring and function of the Golgi appa-
ratus. A third mechanism for PKD1 activation is through
caspase-mediated cleavage during the induction of apoptosis
by genotoxic drugs [13].
Recent ¢ndings from our [21] and other [27] laboratories
have shown that PKD1 is phosphorylated on multiple sites
during in vivo activation. Five phosphorylation sites have
been identi¢ed in PKD1: two sites in the regulatory domain,
two in the catalytic domain, and one at the C-terminus.
Ser744 and Ser748 (both in the activation loop) play a crucial
role in the activation of PKD1. Substitution of these amino
acids with alanine completely blocks PKD activation, while
substitution with glutamic acid (mimicking phosphorylation)
causes a constitutive activation [28]. Ser916 (C-terminus) is an
autophosphorylation site, not required for activation but
rather regulating the conformation of PKD1. Ser203 (regula-
tory domain) is an autophosphorylation site and is located in
the region that interacts with 14-3-3 proteins. Ser255 (in the
regulatory domain) is a transphosphorylation site, targeted by
PKC or a PKC-activated kinase. Remarkably, in vivo stimu-
lation with PDBu of a PKD S255E mutant no longer requires
PKC phosphorylation.
The exact role of each phosphorylation event in the activa-
tion process of PKD1 is still speculative. Ser744/748 are
thought to be phosphorylated by PKCO, PKCR or PKCa,
but in a recent report [26] it is shown that Ser748 can be
slowly autophosphorylated, and that PKCO can serve as a
second site kinase for Ser744. Perhaps autophosphorylation
at Ser748 can positively in£uence Ser744 for transphosphor-
ylation by PKCO. In addition, the PKC isoform(s) responsible
for the phosphorylation of PKD will likely be cell type-depen-
dent, simply because not all PKC isozymes are expressed in
each cell type.
As for PKD1, it has recently been shown that PKD2 also
becomes activated downstream of G-protein coupled recep-
tors (GPCRs), through the activation of PLCQ, which in
turn activates PKCK, PKCO, or PKCR [29]. For PKD2, three
phosphorylation sites have been identi¢ed so far: Ser876 cor-
responding to Ser916 in PKD1 [3], and Ser706 and Ser710
(activation loop) corresponding to Ser744 and Ser748 in
PKD1 [29]. Very recently it has been found that PKD3 is
also activated through a DAG^PLC^PKC-dependent path-
way in B-cells [30]. PKCO, PKCa, and PKCR are candidates
for the transphosphorylation of the activation loop Ser731
and Ser735 of PKD3 in this activation event, since cotrans-
fection studies with constitutively active and kinase-dead PKC
isoforms revealed PKD3 activation loop phosphorylation by
these three novel PKCs. In contrast to PKD1 and PKD2,
PKD3 does not seem to have an autophosphorylation site
at its C-terminus.
3. Intracellular localization of PKD and translocation to
di¡erent organelles
The association of PKD with other proteins or lipids
through its regulatory subdomains is important for its subcel-
Fig. 1. Modular structure of PKD family members: PKD1/PKCW, PKD2, PKD3/PKCX. AP, alanine- and proline-rich domain; P, proline-rich
domain; S, serine-rich domain; CYS, cysteine-rich Zn ¢nger domain; AC, acidic domain; PH, pleckstrin homology domain; KINASE, kinase
catalytic domain.
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lular localization. Through these domains PKD can be re-
cruited to multiple cellular compartments (Fig. 2), such as
the plasma membrane, the Golgi apparatus or the nucleus,
in response to speci¢c stimuli. In resting cells a large fraction
of PKD1 resides in the cytosol, while a smaller fraction can be
found in the Golgi. In some specialized cells, PKD1 has also
been found in mitochondria [31] and in secretory granules
[32]. The two Zn ¢ngers of PKD1 have di¡erent lipid binding
speci¢cities [25], which has consequences for targeting PKD1
to di¡erent cellular locations. Upon stimulation of cells with
mitogenic GPCR agonists, PKD1 is translocated initially
from the cytosol to the plasma membrane (through its second
Zn ¢nger), followed by a rapid dissociation from the plasma
membrane, which requires PKC activation and phosphoryla-
tion of the PKD1 activation loop. Finally, PKD1 transiently
accumulates in the nucleus (mediated by the second Zn ¢n-
ger). The export from the nucleus requires the PH domain
[33]. PKD localization studies should be interpreted with
some caution because they were performed by overexpressing
green £uorescent protein^PKD constructs. PKD1 has also
been reported to bind to the TGN. This association is medi-
ated by the ¢rst cysteine-rich domain of PKD1 and is depen-
dent on local DAG production [34,35]. Unlike other PH do-
main-containing kinases, such as PKB/Akt, PKD1 does not
need its PH domain for membrane translocation [32,36], nor
for Golgi localization [34]. This is in agreement with the lack
of evidence for interaction of the PKD1 PH domain with
those phosphorylated inositol lipids that are important for
the recruitment of PKB to the plasma membrane. To discover
the exact relationship between the spatio-temporal regulation
of PKD1 translocations and its biological functions, more
detailed investigations are needed.
Recently, PKD3 was also shown to translocate rapidly to
the plasma membrane in response to phorbol-12,13-myristate
acetate (PMA), where it becomes active. In response to PMA,
PKD3 stays at the plasma membrane even at late time points,
s 10 min. B-cell receptor (BCR) cross-linking also induced
translocation and activation of PKD3, but very shortly after
translocation (6 30 s) PKD3 is found both at the plasma
membrane and in the cytosol [30].
4. Substrate and inhibitor speci¢city of PKD
Little is known about direct targets downstream of the
PKD family members, and the lack of speci¢c inhibitors
makes the research in this ¢eld even more di⁄cult.
Only a few physiological substrates of PKD1 are identi¢ed.
Kidins220 (kinase D interacting substrate of 220 kDa), an
integral membrane protein selectively expressed in brain and
neuroendocrine cells, is phosphorylated by PKD1 at serine
919 [16]. PKD1 was also suggested to phosphorylate c-Jun
at sites di¡erent from those phosphorylated by Jun N-termi-
nal kinase (JNK), downregulating in this manner the JNK
pathway [37]. Further investigations, however, are required
to prove that this is the in vivo mechanism. Recently, another
in vivo substrate for PKD1 was identi¢ed. The RAS e¡ector
Fig. 2. Nucleoplasmatic shuttling and Golgi translocation. Upon stimulation of cells with mitogenic GPCR agonists PKD is initially translo-
cated from the cytosol to the plasma membrane through its second cysteine-rich Zn ¢nger. PKD dissociates rapidly from the plasma membrane
when it is activated and phosphorylated at the activation loop through PKC. Relocation in the cytosol is followed by accumulation of PKD in
the nucleus, mediated by its second cysteine-rich Zn ¢nger. Export from the nucleus requires an intact PH domain and a Crm-1-dependent nu-
clear export mechanism. Recruitment of PKD to the TGN is mediated by its ¢rst cysteine-rich Zn ¢nger domain and depends on locally pro-
duced DAG. PKD*, activated PKD; nPKC, novel PKCs; PLC, phospholipase C; Cys, cysteine-rich domain; PH, pleckstrin homology do-
main; P, phosphate.
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RIN1 is phosphorylated by PKD1 at serine 351, thereby caus-
ing dissociation from RAS and stimulating binding of RIN to
14-3-3 proteins. This in turn allows Raf to interact with RAS
[15].
Since no other endogenous substrates have been identi¢ed
so far, little is known about the substrate speci¢city of the
PKD family members. Using an oriented peptide library ap-
proach, substrate speci¢cities were determined for the di¡er-
ent PKC isoforms including PKCW/PKD1 [6]. PKD1 prefers a
basic residue at position 33 and a hydrophobic residue (va-
line, in contrast to the phenylalanine for PKCs) at position +1
with respect to the phosphorylatable serine. PKD1 was unique
in that it selected for substrates with hydrophobic residues at
34, +2, +3, +4, and +5, where PKCs prefer more basic res-
idues, and the most critical residue for selectivity of PKD1 is a
leucine at 35.
An important feature in the search for downstream path-
ways and more speci¢c substrates of the PKD family members
is the need for speci¢c inhibitors. So far, no speci¢c inhibitor
is known for any of the isozymes. In several reports the com-
bination of Go«6976 and Go«6983 (staurosporine-related com-
pounds) was used; the former is an inhibitor of cPKCs and of
PKD1 (IC50 = 20 nM), the latter is an inhibitor of cPKCs and
nPKCs but a very weak inhibitor for PKD1 (IC50 = 20 WM)
[7]. Remarkably, the staurosporine-derived compound, bisin-
dolylmaleimide I (GF-109203X), which is only a weak inhib-
itor for PKD1 [7], inhibits the autokinase activity of PKD2 by
about 75% [29]. Thus, despite the high percentage of homol-
ogy in the catalytic subunit of PKD1 and PKD2, there seems
to be a functional di¡erence with respect to their inhibitor
sensitivity.
5. Cellular signaling and importance in biological functions
5.1. Signaling pathways activating PKD
Many agents activate PKD in vivo through a PKC-depen-
dent pathway [38^41] : tumor-promoting phorbol esters, DAG
and analogs, bryostatin, platelet-derived growth factor
(PDGF), neuropeptides, oxidative stress, convulxin and
thrombin, ATP and gastrin or cholecystokinin. Recently, it
has been shown that PKD2 is also activated via PKCK,
PKCO or PKCR through the CCKB/gastrin receptor in human
gastric cancer cells [29]. In addition, it was shown that PKD1
is activated through B- and T-cell cross-linking [17] and
through an IgE plus Ag stimulus in mast cells [42]. A recent
report also shows that PKD3 is activated through BCR cross-
linking [30]. Tumor necrosis factor K (TNF-K) [12], doxoru-
bicin [43] and other genotoxic chemotherapeutic agents also
activate PKD1 [13], but the role of PKC in these signaling
pathways is unknown.
Clearly, the PLC^DAG^PKC pathway plays a major role
in the activation of PKD by several agents. Although the
second cysteine-rich domain of PKD binds directly to DAG,
this is not the main activation mechanism following stimula-
tion of PLC. In case of classical and novel PKCs, a pseudo-
substrate sequence is replaced from the substrate binding site
during DAG binding, creating an active enzyme. However,
this PKC activation is not retained during immunoprecipita-
tion, because DAG is released. Since PKD preserves its activ-
ity after being immunoprecipitated, and because of the ab-
sence of such a pseudosubstrate domain, it seems that DAG
binding in PKD mainly serves to localize the enzyme to spe-
ci¢c cellular targets. The activation itself is predominantly
mediated by phosphorylation events. This is reminiscent of
the activation mechanism of PKB/Akt. After PI3-kinase stim-
ulation, PKB is recruited to the membrane through interac-
tion of its PH domain with PtdIns(3,4,5)P3 or PtdIns(3,4)P2.
The interaction alters its conformation and PKB becomes
accessible for phosphorylation and activation by PDK1 and
PDK2 [44]. Although PKD possesses a PH domain, this do-
main is not responsible for its recruitment to the plasma mem-
brane, but the parallel with the mechanism of PKB activation
can be drawn: DAG, produced after PLC activation, binds to
Zn ¢nger 2 of PKD and ensures the recruitment of the kinase
at the plasma membrane, where it can be phosphorylated by
PKCs.
5.2. Signaling pathways a¡ected by PKD, and their biological
importance
5.2.1. PKD: role in control of cell growth and survival versus
apoptosis. PKD1 expression is correlated with the prolifera-
tive state of mouse keratinocytes. Moreover, mouse skin car-
cinomas display an increased PKD1 expression level and for
NIH3T3 ¢broblasts overexpressing PKD1, the correlation
with proliferation could also be observed [10]. In Swiss3T3
cells, overexpression of PKD1 potentiates DNA synthesis
and cell growth induced by bombesin, vasopressin, or phorbol
esters [11].
PKD1 seems to have a prominent role in the mitogen-acti-
vated ERK (extracellular signal regulated kinase) and JNK
pathways. A model for the activation of ERK through
PKD1 has recently been proposed [38] : PKC-dependent acti-
vation of PKD1 induces translocation of PKD1 to the plasma
membrane, where it can phosphorylate RIN1, a protein that
associates with Ras and 14-3-3 proteins (also a binding part-
ner for PKD1). Through phosphorylation of RIN1, the asso-
ciation with 14-3-3 could become more intense; therefore Ras
can dissociate and is free to be activated such that it can
stimulate the Raf^MEK^ERK pathway. The inhibitory e¡ect
of PKD1 on JNK signaling has been reported before and has
been implicated in the PDGF-mediated suppression of the
epidermal growth factor (EGF) receptor signaling to JNK.
PKD1 overexpression in HEK293 cells causes the phosphor-
ylation of the EGF receptor, which prevents the further sig-
naling to JNK [45]. Another study reported a negative regu-
lation of JNK through its physical interaction with activated
PKD1, leading to the inhibition of JNK and c-jun phosphor-
ylation at sites distinct from those phosphorylated by JNK,
thereby inhibiting the ability of c-Jun to further regulate pro-
liferation and di¡erentiation [37]. It is possible that both
mechanisms of inhibition work in parallel. One should bear
in mind that these observations rely on overexpression studies,
and hence the physiological importance is unknown.
Besides its function in proliferation, PKD1 seems to have
an important role in cell survival: PKD1 is activated by oxi-
dative stress and induces survival pathways. It has been sug-
gested that oxidative stress leads to activation of Src and
PLC, which stimulates several PKCs, leading to PKD1 acti-
vation [46]. Recently, a slightly di¡erent model has been pro-
posed: reactive oxygen species activate the Src^Abl signaling
pathway, leading to tyrosine phosphorylation of PKD1 in the
PH domain and subsequent activation; at the same time oxi-
dative stress could also lead to activation of PKCs, which
activate PKD1 through activation-loop phosphorylation.
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These two events would result in a fully activated PKD1,
mediating activation of IKKL and degradation of IUBK, re-
sulting in NF-UB activation and cell survival [20]. Besides
controlling the activation of PKD1, the tyrosine phosphory-
lation of the PH domain in PKD1 could also serve as a rec-
ognition site for interacting proteins (through SH2 or PTB
domains), thereby bringing these protein(s) in the proximity
of their upstream and/or downstream e¡ectors. Surely, further
work is required to examine these possibilities. This pro-sur-
vival e¡ect of PKD, however, disappears when PKD under-
goes proteolysis upon treatment of cells with L-D-arabinofur-
anosyl cytosine (ara-C) or other genotoxic drugs [13]. When
human U-937 myeloid leukemia cells are treated with these
agents, PKD1 is cleaved by caspases and this further sensitizes
the cells to apoptosis.
5.2.2. PKD function in the immune response. PKD’s role
in immune regulation is supported by several studies: BCR or
T-cell receptor (TCR) cross-linking causes activation of PKD1
[17] ; PKD1 rapidly relocalizes to the plasma membrane in
B-cells and mast cells after antigen receptor triggering [32],
and endogenous PKD1 exhibits a constitutive association
with Btk [47]. The activation of PKD1 in BCR cross-linking
depends on Syk and PLCQ activity and is also regulated by
Btk. It was suggested that PKD1 could function in a feedback
loop, negatively regulating the BCR by reducing the ability of
Syk to phosphorylate PLCQ. Recently, it was found that
PKD3 is abundantly expressed in B-cells, and as for PKD1,
BCR engagement results in strong activation of PKD3. PLCQ
and novel PKC isoforms are required in this activation pro-
cess [30].
5.2.3. PKD importance in Golgi organization and func-
tion. PKD1 has been implicated in the regulation of Golgi
organization [35]. The marine sponge metabolite ilimaquinone
and GLQ both cause complete fragmentation of the pericen-
triolar Golgi membranes. This process is e¡ectively inhibited
by PKD1 peptide substrates. Moreover, immunoprecipitated
PKD1 shows stimulated kinase activity due to direct interac-
tion of the PH domain with GLQ. Altogether, these data sug-
gest that PKD1 is a component of the Golgi fragmentation
pathway. In the same study it was found that PKD1 activity is
required for protein transport to the plasma membrane. Ve-
sicular stomatitis virus G-protein transport was inhibited by
PKD1 peptide substrate or by the PH domain of PKD1. The
PKD1 involvement in ¢ssion of transport carriers from the
TGN to the plasma membrane has gained extra support by
the ¢nding that a kinase-inactive form of PKD1 causes exten-
sive tubulation of the TGN and inhibits the detachment of
cargo-containing vesicles from the TGN to the cell surface [9].
It remains unclear how PKD1 regulates this ¢ssion process,
but recently a model has been proposed [48] : lipid metabo-
lism, PKD1 activity and its recruitment of e¡ectors are all
thought to play a pivotal role in a vesicle budding machine.
In this respect, the interaction of PI-4-kinase and PI-4,5-ki-
nase with the Zn ¢nger region of active PKD1 could be of
importance [49]. PKD1 might act as a sca¡old to recruit these
enzymes to the Golgi, where they produce phosphorylated
inositol lipids. Phosphatidic acid (PA) is also implicated in
¢ssion promotion [50]. DAG, which recruits PKD1 to the
TGN through its binding to Zn ¢nger 1, could, in a second
step, become the substrate for DAG kinases that convert
DAG to PA. The production of these phosphorylated inositol
lipids and/or PA would lead to the formation of a vesicle,
budding o¡ from the TGN membrane.
5.2.4. Possible role for PKD in cell shape regulation and
invasion. In invasive breast cancer cells PKD1 forms a com-
plex with cortactin and paxillin, associated with invadopodial
membranes that extend into the extracellular matrix [51]. In-
vadopodia are actin-containing protrusions extending into the
matrix and participating in active proteolytic matrix degrada-
tion. Cortactin has been suggested to play a role in cell mo-
tility and cellular invasion, while the exact role of paxillin
remains mainly unidenti¢ed. The function of cortactin might
be modulated by paxillin and PKD1 in this invasion-related
complex. Further studies should clarify questions such as:
What is the exact function of PKD1 in this complex? Is
PKD1 a modulator of complex formation or does it regulate
the protease activity? Is PKD1 phosphorylating substrates in
these invadopodia?
On top of the ¢ndings that PKD1 could play a role in cell
shape modulation of invasive cells, PKD1 was also shown to
phosphorylate Kidins220, a protein abundant in neurite tips
and growth cones of PC12 pheochromocytoma cells, which
could possibly point to a role for PKD1 in cytoskeletal reor-
ganization [H].
6. Perspectives
While we currently have a reasonable understanding of the
regulation of PKD1 enzyme activity by PKC-dependent path-
ways, much remains to be discovered regarding the PKD en-
zyme family. First, it can be expected that the di¡erent family
members will not all have the same tissue distribution. The
functional roles for PKD1, 2 and 3 in di¡erent tissues still
need a lot of exploration. Second, intracellular localization
studies have so far focused only on PKD1. It is very well
possible that localization of PKD2 and 3 could be regulated
in subtly di¡erent fashions. Third, su⁄cient di¡erences exist in
the regulatory domain of the PKDs to already predict the
existence of common, but also subtype-speci¢c interactors
for these enzymes. These still largely remain to be identi¢ed.
And ¢nally, a much better understanding of the role of this
kinase family in cellular signaling will be gained from a sys-
tematic exploration of their in vivo substrates.
Nevertheless, the discovery of the PKD family of enzymes
has put a very important novel set of players on the map of
signal transduction.
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